Taysha Gene Therapies (NASDAQ:TSHA) and ADMA Biologics (NASDAQ:ADMA) Critical Survey

Taysha Gene Therapies (NASDAQ:TSHA) and ADMA Biologics (NASDAQ:ADMA) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, institutional ownership and profitability.

Risk and Volatility

Taysha Gene Therapies has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500. Comparatively, ADMA Biologics has a beta of 0.7, indicating that its share price is 30% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings for Taysha Gene Therapies and ADMA Biologics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Taysha Gene Therapies	1	0	12	2	3.00
ADMA Biologics	0	3	3	0	2.50

Taysha Gene Therapies presently has a consensus price target of $12.77, indicating a potential upside of 222.46%. ADMA Biologics has a consensus price target of $18.67, indicating a potential upside of 74.78%. Given Taysha Gene Therapies’ stronger consensus rating and higher possible upside, analysts clearly believe Taysha Gene Therapies is more favorable than ADMA Biologics.

Profitability

This table compares Taysha Gene Therapies and ADMA Biologics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Taysha Gene Therapies	N/A	-56.19%	-41.84%
ADMA Biologics	32.98%	40.17%	26.97%

Insider and Institutional Ownership

77.7% of Taysha Gene Therapies shares are owned by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are owned by institutional investors. 3.5% of Taysha Gene Therapies shares are owned by company insiders. Comparatively, 3.9% of ADMA Biologics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Taysha Gene Therapies and ADMA Biologics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Taysha Gene Therapies	$9.77 million	132.07	-$109.00 million	($0.42)	-9.43
ADMA Biologics	$510.17 million	4.69	$146.93 million	$0.70	15.26

ADMA Biologics has higher revenue and earnings than Taysha Gene Therapies. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Summary

ADMA Biologics beats Taysha Gene Therapies on 8 of the 15 factors compared between the two stocks.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

About ADMA Biologics

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.